Relationship between BRAF V600E mutation and clinicopathological features of papillary thyroid carcinoma patients combined with chronic lymphocytic thyroiditis / 肿瘤研究与临床

ABSTRACT

Objective To investigate the relationship between BRAF V600E mutation and clinicopathological features of papillary thyroid carcinoma (PTC) combined with chronic lymphocytic thyroiditis (CLT). Methods The clinical data of 168 PTC patients combined with Hashimoto thyroiditis who received radical surgery treatment in Beijing Caner Hospital from November 2013 to July 2016 were analyzed retrospectively. Sanger sequence was used to detect the status of BRAF V600E mutation. Then the patients were divided into BRAF V600E mutation positive (the observation group) and the mutation negative group (the control group). The clinicopathological features between the two groups were compared. Results The proportion of gender, age, calcification, lymphatic metastasis and extra gland invasion incidence had no significant difference between the observation group and the control group (χ2= 0.234, 1.139, 0.650, 1.262 and 1.665 respectively, all P＞0.05). Moreover, the differences of tumor size, tumor shape and tumor number in both groups were statistically significant (χ2= 7.071, 3.877 and 6.968 respectively, all P＜ 0.05). Logistic regression analysis showed that there was no statistical difference between the patients with BRAF V600E mutation or without in tumor number and central lymph node metastasis ( OR= 0.263, 95 % CI 0.049-1.402, P=0.118; OR=2.152, 95 % CI 0.666-6.956, P=0.200). Conclusion BRAF V600E mutation has no significant effect on clinicopathological features of PTC patients combined with CLT.